Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Vincent M. Chung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9475-808X; OpenAlex author ID A5022022603, A5041133739, A5135137912. Sources: ClinicalTrials.gov.

Their work

Papers
43 (first author 3, last author 3)
Trials
10 (principal investigator on 10)
Grants
0
Labs led
1
Collaborators
236
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: 1 trial · 2012: none · 2013: none · 2014: 1 paper, 1 trial · 2015: 1 paper, 1 trial · 2016: 3 papers, 1 trial · 2017: 4 papers · 2018: 4 papers · 2019: 4 papers · 2020: 1 paper · 2021: 4 papers, 1 trial · 2022: 5 papers, 1 trial · 2023: 2 papers · 2024: 2 papers, 2 trials · 2025: 4 papers, 1 trial · 2026: 8 papers

Papers 43

  1. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.3840↗
  2. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  3. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  4. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  5. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  6. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  7. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. First author DOI 10.1093/oncolo/oyag023↗
  8. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  9. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  10. Pancreatic Cancer Immunotherapy: A Team-Based Approach. Last author DOI 10.1007/978-3-031-97242-3_11↗
  11. Therapeutic Targeting of Oncogene-Induced Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.02.038↗
  12. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  13. Neoadjuvant treatment for pancreatic cancer: Controversies and advances. First author DOI 10.1016/j.ctarc.2024.100804↗
  14. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  15. Real-world data validation of the PurIST pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implications Co-author DOI 10.1101/2023.02.23.23286356↗
  16. Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data. Co-author DOI 10.3390/jpm13091377↗
  17. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and be… Co-author DOI 10.1002/cam4.4768↗
  18. Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215801↗
  19. Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. Co-author DOI 10.1089/jpm.2021.0187↗
  20. B7H6 Serves as a Negative Prognostic Marker and an Immune Modulator in Human Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.814312↗
  21. Advances in Radiation Oncology for Pancreatic Cancer: An Updated Review. Co-author DOI 10.3390/cancers14235725↗
  22. Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. Co-author DOI 10.1002/jso.26415↗
  23. Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma✰. Last author DOI 10.1016/j.ctarc.2021.100397↗
  24. Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.678617↗
  25. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  26. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Co-author DOI 10.1016/s1470-2045(20)30074-7↗
  27. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1002/cam4.2491↗
  28. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. Co-author DOI 10.1200/po.19.00115↗
  29. The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. Co-author DOI 10.21037/jgo.2019.01.19↗
  30. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  31. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Co-author DOI 10.1007/s10689-017-0019-5↗
  32. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Co-author DOI 10.1158/1078-0432.ccr-18-0531↗
  33. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Co-author DOI 10.1186/s40169-018-0210-9↗
  34. Targeted Therapies for Pancreatic Cancer. First author DOI 10.3390/cancers10020036↗
  35. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomize… Co-author DOI 10.1001/jamaoncol.2016.5383↗
  36. Current and future therapies for advanced pancreatic cancer. Last author DOI 10.1002/jso.24623↗
  37. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Kno… Co-author DOI 10.18632/oncotarget.13225↗
  38. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  39. Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. Co-author DOI 10.1007/s00520-016-3155-9↗
  40. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  41. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. Co-author DOI 10.1097/mpa.0000000000000379↗
  42. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-015-1679-3↗
  43. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗

Trials 10

  1. STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cance… Principal investigator NCT06626256↗
  2. Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer Principal investigator NCT06454383↗
  3. Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers Principal investigator NCT06524973↗
  4. AOH1996 for the Treatment of Refractory Solid Tumors Principal investigator NCT05227326↗
  5. Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer Principal investigator NCT04887805↗
  6. Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating P… Principal investigator NCT02336087↗
  7. Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Principal investigator NCT02432963↗
  8. Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Principal investigator NCT01741597↗
  9. Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Principal investigator NCT01191684↗
  10. Dasatinib in Treating Patients With Stage IV Pancreatic Cancer Principal investigator NCT00544908↗

Closest collaborators

The 25 strongest of 236 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Laleh Golkar Melstrom · 7 shared papers, 2019–2026 · strength 1.31
  2. Mustafa Raoof · 7 shared papers, 2019–2026 · strength 1.21
  3. Eileen Mary O'Reilly · 7 shared papers, 2017–2026 · strength 1.15
  4. Daniel D. Von Hoff · 5 shared papers, 2021–2026 · strength 0.97
  5. Erkut Hasan Borazanci · 5 shared papers, 2021–2026 · strength 0.87
  6. Tanios Bekaii‐Saab · 5 shared papers, 2015–2026 · strength 0.86
  7. Zev A. Wainberg · 4 shared papers, 2024–2026 · strength 0.81
  8. Dana Backlund Cardin · 7 shared papers, 2017–2026 · strength 0.79
  9. Ajay Goel · 4 shared papers, 2021–2026 · strength 0.76
  10. Derek Cridebring · 4 shared papers, 2021–2026 · strength 0.71
  11. Teresa Mercade Macarulla · 3 shared papers, 2026 · strength 0.70
  12. Mitsuro Kanda · 3 shared papers, 2026 · strength 0.66
  13. Song Cheol Kim · 3 shared papers, 2026 · strength 0.66
  14. Shubham Pant · 3 shared papers, 2026 · strength 0.65
  15. Andrew Eugene Hendifar · 7 shared papers, 2017–2026 · strength 0.63
  16. Carlos Roberto Becerra · 3 shared papers, 2025–2026 · strength 0.60
  17. Haiyong Han · 3 shared papers, 2025–2026 · strength 0.60
  18. Elena Gabriela Chiorean · 6 shared papers, 2014–2026 · strength 0.57
  19. Andrew H. Ko · 6 shared papers, 2014–2026 · strength 0.56
  20. Christos K Fountzilas · 4 shared papers, 2019–2026 · strength 0.50
  21. Andrew M. Lowy · 6 shared papers, 2014–2026 · strength 0.46
  22. Douglas Dias e Silva · 1 shared paper, 2024 · strength 0.46
  23. Hassan A. Hatoum · 2 shared papers, 2026 · strength 0.46
  24. Andrew Scott Paulson · 2 shared papers, 2026 · strength 0.46
  25. Roberto Pazo-Cid · 2 shared papers, 2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.